Relative bioavailability of scopolamine dosage forms and interaction with dextroamphetamine.
The NASA Reduced Gravity Office (RGO) uses scopolamine (SCOP) alone and in combination with dextoamphetamine (DEX) to treat motion sickness symptoms during DC-9 parabolic flights. The medications are sometimes dispensed as custom dosage forms in gelatin capsules for convenience. Reports of treatment failure during flights by the flight surgeons suggest that these formulations may be less efficacious for the treatment of motion sickness due to unreliable and inadequate bioavailability. We estimated bioavailability of four different oral formulations used by the NASA RGO physicians for the treatment of motion sickness.
Boyd
Jason L
JL
Universities Space Research Association, Houston, TX, USA.
Du
Brian
B
Vaksman
Zalman
Z
Locke
James P
JP
Putcha
Lakshmi
L
D000284:Administration, Oral; D000328:Adult; D000932:Antiemetics / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics*; D001682:Biological Availability; D002214:Capsules; D003071:Cognition / Q000187:drug effects*; D003913:Dextroamphetamine / Q000008:administration & dosage*; D004338:Drug Combinations; D004347:Drug Interactions; D005780:Gelatin; D006801:Humans; D008297:Male; D008875:Middle Aged; D011930:Reaction Time; D012463:Saliva / Q000378:metabolism; D012601:Scopolamine / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D013026:Space Flight; D018489:Space Motion Sickness / Q000517:prevention & control*; D013607:Tablets; D017211:Treatment Failure; D014481:United States; D018557:United States National Aeronautics and Space Administration
D000932:Antiemetics; D002214:Capsules; D004338:Drug Combinations; D013607:Tablets; D005780:Gelatin; D012601:Scopolamine; D003913:Dextroamphetamine